News

SOLCO HEALTHCARE INTRODUCES OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE Tablets

April 24, 2017

CRANBURY, NJ -- Solco Healthcare today announced the launch of generic version of Daiichi-Sankyo’s Benicar-HCT ® , Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20mg/12.5mg, 40/12.5mg and 40mg/25mg. Solco received its final approval by the U.S. FDA for its abbreviated New Drug Application (ANDA) via its parent company Prinston Pharmaceutical Inc. Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for the treatment of hypertension to lower blood pressure, and are not indicated for the initial therapy of hypertension. “As one of fastest growing US generic companies, we are pleased to be the first wave of companies offering a low cost, high quality alternative to patients in the US,” said Hai Wang, President of Solco Healthcare. According to QuintilesIMS, total market sales for all three strengths combined for the last twelve months ending December 2016 were $780.1 million.

About Solco Healthcare US, LLC

Solco is a generic pharmaceutical company that develops, manufactures and markets quality, cost-effective and innovative generic pharmaceuticals for patients who need them. Solco offers a broad range of generic prescription products in many therapeutic categories, including differentiated, high barrier-to-entry, specialty drug products. Solco is a fully owned subsidiary of Prinston Pharmaceutical Inc. (www.prinstonpharm.com). Together we strive to offer greater access to affordable medications that you can trust. For press release and other company information, visit www.solcohealthcare.com.

SOLCO HEALTHCARE US, INTRODUCES DOXYCYCLINE HYCLATE DELAYED-RELEASE TABLETS, 150mg and 200mg

11/15/2016

CRANBURY, NJ -- Solco Healthcare is proud to announce its FDA approval for Doxycycline Hyclate delayed-release tablets, 150mg and 200mg, which are AB-rated equivalents to Doryx® by Mayne Pharmaceutical.

“This new product launch demonstrates the capabilities of the Prinston/Solco team in developing, manufacturing and bringing a difficult to formulate product to market. As one of fastest growing US generic companies, we are pleased to be the first wave company to make high-quality Doxycycline Delayed Release tablets in 200mg and 150mg strengths available for patients in the US,” said Hai Wang, President of Solco Healthcare. Doxycycline Hyclate DR tablet is an oral antibacterial drug that is used in combination with other medicines to treat severe acne. According to IMS Health, total market sales for both strengths for the last twelve months ending September 2016 were $147.7 million.

Solco Healthcare will market Doxycycline Hyclate delayed-release tablets in 100 count bottles for the 150mg strength and in 60 count bottles for the 200mg strength. Solco anticipates launching these products in the very near future. Please contact your Solco Healthcare National Accounts Director or customer service at 1-888-869-8008 for more information.

SOLCO HEALTHCARE U.S. ANNOUNCES THE APPROVAL OF GENERIC VFEND ® TABLETS IN THE UNITED STATES

8/12/2016

CRANBURY, NJ – August 11, 2016 – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Vfend ® Tablets (Voriconazole Tablets), 50 mg and 200 mg. The Company is preparing for the commercialization of this product and expects to launch the product soon.

"We are pleased to receive FDA approval of generic voriconazole tablets, a product that was developed by our parent company, Prinston Pharmaceutical and manufactured in our Linhai, China facility," said Hai Wang, President of Solco. "This is our fourth Abbreviated New Drug Applications (ANDA) approval in 2016, as we continue to strengthen our presence within the US generic market by providing high quality medicines at affordable prices.”

According to IMS Health (NSP), U.S. brand and generic sales of voriconazole tablets products were approximately $89.4 million for the 12 months ending in June 2016.

About Solco Healthcare U.S. Solco Healthcare U.S., headquartered in Cranbury, New Jersey, is an industry leader in marketing and distributing generic pharmaceuticals. Solco is committed to providing our customers with high quality, cost effective and innovative generic prescription medications. Solco offers a broad range of generic prescription products in many therapeutic categories, including differentiated, specialty drug products.

Solco is a fully owned subsidiary of Prinston Pharmaceutical Inc. www.prinstonpharm.com. Together we strive to offer greater access to affordable medications that you can trust.

*******

Contacts: Chris Keith, Senior Vice President, Marketing & Business Development
Phone: (609) 451-1000
Email: chris.keith@solcohealthcare.com